Skip to main content

Main menu

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC

User menu

Search

  • Advanced search
JPN
  • CMAJ JOURNALS
    • CMAJ
    • CMAJ Open
    • CJS
    • JAMC
JPN

Advanced Search

  • Home
  • Issues
    • Issue in progress
    • Issues by date
  • Sections
    • Editorial
    • Review
    • Research
    • Commentary
    • Psychopharmacology for the Clinician
    • Letters to the Editor
  • Topic Collections
  • Instructions for Authors
    • Overview for authors
    • Submission checklist
    • Editorial policies
    • Publication fees
    • Submit a manuscript
    • Dr. Francis Wayne Quan Memorial Prize
    • Open access
  • Alerts
    • Email alerts
    • RSS
  • About
    • General information
    • Staff
    • Editorial Board
    • Contact
  • Subscribe to our alerts
  • RSS feeds
  • Follow JPN on Twitter
Psychopharmacology for the Clinician

The treatment of bipolar patients with elevated impulsivity and suicide risk

Matthew E. Sloan, Adam Iskric and Nancy C. Low
J Psychiatry Neurosci July 01, 2014 39 (4) E34-E35; DOI: https://doi.org/10.1503/jpn.130274
Matthew E. Sloan
Department of Psychiatry, McGill University, Montréal, Que., Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam Iskric
Department of Psychiatry, McGill University, Montréal, Que., Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy C. Low
Department of Psychiatry, McGill University, Montréal, Que., Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

A 22-year-old man with bipolar II disorder was referred for follow-up at the mood disorders clinic of a tertiary care centre. He was first seen by a psychiatrist at age 20 when he had a 6-week episode of decreased need for sleep; increased energy; difficulty concentrating; and impulsive spending, including purchasing a new house. This episode resolved without treatment. A year later, at age 21, he experienced depressive symptoms, including low mood, decreased appetite, weight loss, low energy and insomnia. He began to have increasing suicidal thoughts and developed an elaborate suicide plan. He purchased a plane ticket to his hometown, where he planned to jump from a high-rise hotel. Prior to leaving for his flight, he called a friend and disclosed his plan. His friend called an ambulance and he was brought to the hospital. This is when he received the diagnosis of bipolar II disorder and was started on quetiapine XR for the depressive episode.

Upon the patient’s referral to our mood disorders clinic 1 year later, we confirmed the diagnosis of bipolar II disorder. At this time, he was euthymic and denied suicidal ideation. During our assessment he reported a longstanding history of impulsive behaviour, including spur-of-the-moment spending, physical altercations and sexual encounters. His level of impulsivity on the Barratt Impulsiveness Scale (BIS-11) was 91, which is an elevated level compared with healthy men, who score an average of 62.8.1 As the patient was no longer interested in taking quetiapine XR owing to side effects, he was started on lithium. He was compliant with treatment and remained euthymic for 2 months, but was lost to follow-up after a trip abroad.

Our patient’s case highlights the potential high lethality of suicidal ideation and planning in individuals with bipolar II disorder and elevated impulsivity. Several studies have reported that patients with bipolar disorder score higher on impulsivity measures than healthy controls.2,3 Furthermore, impulsivity may be associated with suicide attempts in these patients. Three studies have reported a significant association between BIS-11 scores and suicide attempts in patients with bipolar disorder,3–5 whereas 1 study has reported a trend toward significance6 and 3 others have found no association.7–9 Unfortunately, most studies examining impulsivity in patients with bipolar disorder do not distinguish between bipolar I and bipolar II disorder, but the prevalence of suicide attempts is comparable in both subtypes.10

Lithium may be the preferred maintenance pharmacotherapy in patients at high suicide risk, although close clinical follow-up is required given its narrow therapeutic window and potential lethality in overdose. Lithium maintenance treatment has been shown to reduce the frequency of affective episodes in both patients with bipolar I and bipolar II disorder, but may have superior benefits in those with bipolar II disorder.11 Meta-analyses have found that patients with mood disorders treated with lithium have a 4- to 5-fold decrease in the rate of suicide completion than patients on comparison treatments (placebo, anticonvulsants, antidepressants).12,13 Large population-based studies have shown lower rates of suicide attempts in patients treated with lithium than those treated with anticonvulsants.14,15 Lithium’s antisuicidal properties may be at least partially attributed to its effects on impulsivity.16 Rodent models have shown that lithium, but not anticonvulsants, reduces impulsivity on behavioural tasks.17,18 Lithium has also been shown to reduce impulsivity in randomized double-blind trials involving patients with bipolar disorder and pathological gambling19 and in patients with attention-deficit/hyperactivity disorder.20

It is less clear whether other treatments for bipolar disorder have any effect on impulsivity and suicide. Valproate has been used successfully to treat impulsive aggression in patients with disruptive behaviour disorders21 and cluster B personality disorders.22 However, a meta-analysis by the US Food and Drug Administration found that the use of anticonvulsants is associated with higher rates of suicidal behaviour in both psychiatric and non-psychiatric patients.23 Antidepressant use may also be problematic, as exposure to selective serotonin reuptake inhibitors may increase suicide risk in patients with bipolar disorder.24

In conclusion, elevated impulsivity may increase the risk of suicidality in patients with bipolar disorder. Although there are limited data on the treatment of highly impulsive patients, there is evidence that lithium may reduce both impulsivity and suicidality in patients with bipolar disorder. Clinicians treating patients with bipolar disorder should be vigilant during assessment and follow-up for elevated impulsivity as part of a thorough suicide risk assessment and should consider lithium maintenance as a potential strategy.

Footnotes

  • The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patients with similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided. The patient described in this column is a composite with characteristics of several real patients.

  • Competing interested: None declared.

References

    1. Standford MS,
    2. Mathias CW,
    3. Dougherty DM,
    4. et al
    .Fifty Years of the Barratt Impulsiveness Scale: An Update and Review.Pers Individ Dif 2009;47:385–95.
    1. Swann AC,
    2. Anderson JC,
    3. Dougherty DM,
    4. et al
    .Measurement of inter-episode impulsivity in bipolar disorder.Psychiatry Res 2001;101:195–7.
    1. Swann AC,
    2. Lijffijt M,
    3. Lane SD,
    4. et al
    .Increased trait-like impulsivity and course of illness in bipolar disorder.Bipolar Disord 2009;11:280–8.
    1. Mahon K,
    2. Burdick KE,
    3. Wu J,
    4. et al
    .Relationship between suicidality and impulsivity in bipolar I disorder: a diffusion tensor imaging study.Bipolar Disord 2012;14:80–9.
    1. Grunebaum MF,
    2. Ramsay SR,
    3. Galfalvy HC,
    4. et al
    .Correlates of suicide attempt history in bipolar disorder: a stress-diathesis perspective.Bipolar Disord 2006;8:551–7.
    1. Michaelis BH,
    2. Goldberg JF,
    3. Davis GP,
    4. et al
    .Dimensions of impulsivity and aggression associated with suicide attempts among bipolar patients: a preliminary study.Suicide Life Threat Behav 2004;34:172–6.
    1. Oquendo MA,
    2. Waternaux C,
    3. Brodsky B,
    4. et al
    .Suicidal behavior in bipolar mood disorder: clinical characteristics of attempters and nonattempters.J Affect Disord 2000;59:107–17.
    1. Perroud N,
    2. Baud P,
    3. Mouthon D,
    4. et al
    .Impulsivity, aggression and suicidal behavior in unipolar and bipolar disorders.J Affect Disord 2011;134:112–8.
    1. Swann AC,
    2. Dougherty DM,
    3. Pazzaglia PJ,
    4. et al
    .Increased impulsivity associated with severity of suicide attempt history in patients with bipolar disorder.Am J Psychiatry 2005;162:1680–7.
    1. Novick DM,
    2. Swartz HA,
    3. Frank E
    .Suicide attempts in bipolar I and bipolar II disorder: a review and meta-analysis of the evidence.Bipolar Disord 2010;12:1–9.
    1. Tondo L,
    2. Baldessarini RJ,
    3. Hennen J,
    4. et al
    .Lithium maintenance treatment of depression and mania in bipolar I and bipolar II disorders.Am J Psychiatry 1998;155:638–45.
    1. Cipriani A,
    2. Pretty H,
    3. Hawton K,
    4. et al
    .Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials.Am J Psychiatry 2005;162:1805–19.
    1. Baldessarini RJ,
    2. Tondo L,
    3. Davis P,
    4. et al
    .Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review.Bipolar Disord 2006;8:625–639.
    1. Goodwin FK,
    2. Fireman B,
    3. Simon GE,
    4. et al
    .Suicide risk in bipolar disorder during treatment with lithium and divalproex.JAMA 2003;290:1467–73.
    1. Collins JC,
    2. McFarland BH
    .Divalproex, lithium and suicide among Medicaid patients with bipolar disorder.J Affect Disord 2008;107:23–8.
    1. Kovacsics CE,
    2. Gottesman II,
    3. Gould TD
    .Lithium’s antisuicidal efficacy: elucidation of neurobiological targets using endophenotype strategies.Annu Rev Pharmacol Toxicol 2009;49:175–98.
    1. Halcomb ME,
    2. Gould TD,
    3. Grahame NJ
    .Lithium, but not valproate, reduces impulsive choice in the delay-discounting task in mice.Neuropsychopharmacology 2013;38:1937–44.
    1. Ohmura Y,
    2. Tsutsui-Kimura I,
    3. Kumamoto H,
    4. et al
    .Lithium, but not valproic acid or carbamazepine, suppresses impulsive-like action in rats.Psychopharmacology (Berl) 2012;219:421–32.
    1. Hollander E,
    2. Pallanti S,
    3. Allen A,
    4. et al
    .Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders?.Am J Psychiatry 2005;162:137–45.
    1. Dorrego MF,
    2. Canevaro L,
    3. Kuzis G,
    4. et al
    .A randomized, double-blind, crossover study of methylphenidate and lithium in adults with attention-deficit/hyperactivity disorder: preliminary findings.J Neuropsychiatry Clin Neurosci 2002;14:289–95.
    1. Donovan SJ,
    2. Stewart JW,
    3. Nunes EV,
    4. et al
    .Divalproex treatment for youth with explosive temper and mood lability: a double-blind, placebo-controlled cross-over design.Am J Psychiatry 2000;157:818–20.
    1. Hollander E,
    2. Tracy KA,
    3. Swann AC,
    4. et al
    .Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders.Neuropsychopharmacology 2003;28:1186–97.
    1. Food and Drug Administration
    Statistical review and evaluation: antiepileptic drugs and suicidality [report], Available: www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf. accessed 2013 Nov. 23.
    1. Marangell LB,
    2. Dennehy EB,
    3. Wisniewski SR,
    4. et al
    .Case-control analyses of the impact of pharmacotherapy on prospectively observed suicide attempts and completed suicides in bipolar disorder: findings from STEP-BD.J Clin Psychiatry 2008;69:916–22.

Content

  • Current issue
  • Past issues
  • Collections
  • Alerts
  • RSS

Authors & Reviewers

  • Overview for Authors
  • Submit a manuscript
  • Manuscript Submission Checklist

About

  • General Information
  • Staff
  • Editorial Board
  • Contact Us
  • Advertising
  • Reprints
  • Copyright and Permissions
  • Accessibility
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1180-4882.

All editorial matter in JPN represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.
To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected].
View CMA's Accessibility policy.

Powered by HighWire